Academy of Managed Care Pharmacy

Family Heart Foundation Research Finds High-Risk Americans Who Do Not Maintain Guideline Recommended LDL-C Targets Have 44% Higher Rate of Cardiovascular Events

Retrieved on: 
Tuesday, March 21, 2023
Men, Research, General Health, Philanthropy, Pharmaceutical, Consumer, Foundation, Science, Cardiology, Women, Other Philanthropy, Health, Other Science, University of Texas Southwestern Medical Center, AT, AMCP, University Challenge 2013–14, Policy, Cardiovascular disease, LLT, Patient, Circulatory system, Academy of Managed Care Pharmacy, Diagnosis, European Journal of Preventive Cardiology, Poster, American College, CDT, EXPO, Conference, Pharmaceutical industry, Medicine

“Often that means taking the right statin, sometimes it means taking more than one medication.

Key Points: 
  • “Often that means taking the right statin, sometimes it means taking more than one medication.
  • No matter how a person gets there, this study shows that living in the ’safe zone’ when it comes to LDL-C control means fewer cardiovascular events over time.
  • Despite LDL-C being a major modifiable risk factor for cardiovascular disease, most patients do not achieve guideline thresholds and even fewer maintain those levels even if they do achieve them.
  • Key findings showed:
    The Family Heart Database is comprised of real-world diagnostic, procedural, and prescription data from claims and/or laboratory information in the U.S. from 2012 to 2021.

Mallinckrodt to Present New Retrospective Data on Effect of Acthar® Gel (Repository Corticotropin Injection) to Reduce Corticosteroid Use and Burden for Advanced Sarcoidosis at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting

Retrieved on: 
Tuesday, March 21, 2023
Sarcoidosis, European Respiratory Society, AMCP, MNK, Adrenocorticotropic hormone, ERS, Patient, Collection, Annual general meeting, Academy of Managed Care Pharmacy, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Pharmaceutical industry, Cosmetics, Nursing, Mallinckrodt

DUBLIN , March 21, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that an abstract highlighting results from a retrospective analysis evaluating the corticosteroid-sparing effect and reduction of corticosteroid burden of Acthar® Gel (repository corticotropin injection) therapy in patients with advanced sarcoidosis,1 has been selected for a poster presentation at the Academy of Managed Care Pharmacy (AMCP) 2023 Annual Meeting taking place in San Antonio, Texas from March 21-24, 2023.   

Key Points: 
  • Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.
  • The retrospective analysis used data from a large administrative pharmacy and medical claims database (Symphony Health Solutions), including a total of 1,361 sarcoidosis patients (n=735 for Acthar Gel cohort; n=626 for alternative fourth-line cohort) from 2014-2020.
  • Outcomes were compared as change from baseline and Acthar Gel adherence was determined by proportion of days covered in the follow-up period.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical outcomes may not be solely attributable to Acthar.

Prime Therapeutics and Magellan Rx to present seven managed care pharmacy research studies at AMCP conference

Retrieved on: 
Thursday, March 16, 2023
Ranibizumab, DME, Research, Cancer, AMCP, Machine learning, PBM, Therapy, Depression, Cholesterol, Diabetic retinopathy, Commercial, Pharmacy, Prime, Maintenance, Pharmacotherapy, Medicare, Patient, SP, Academy of Managed Care Pharmacy, AMD, Cystic fibrosis, MID, Blue, Medicine, Single (music), Cryptocurrency, Health care, Pharmaceutical industry, Birth control, Health insurance, Bevacizumab

EAGAN, Minn., March 16, 2023 /PRNewswire/ -- Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) and Magellan Rx Management, (Magellan Rx), a Prime Therapeutics company, will present seven research studies at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting, March 21-24 in San Antonio, Texas.

Key Points: 
  • EAGAN, Minn., March 16, 2023 /PRNewswire/ -- Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) and Magellan Rx Management , (Magellan Rx), a Prime Therapeutics company, will present seven research studies at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting , March 21-24 in San Antonio, Texas.
  • Prime and Magellan Rx used integrated medical and pharmacy claims data to evaluate real-world drug utilization and managed care pharmacy programs.
  • "The teams conducting this research at Prime and Magellan Rx include some of the brightest minds in managed care pharmacy focused on whole-person care to not only improve health outcomes but also save health care costs," said Pat Gleason, PharmD, assistant vice president for health outcomes at Prime.
  • "These real-world studies demonstrate that with combined expertise, Prime and Magellan Rx are transforming the pharmacy industry, driving savings and bridging the distance between medical and pharmacy management to close gaps in care and help keep members healthier."

Koya Medical Selected for Poster Presentation of the NILE Clinical Trial, awarded Gold medal at AMCP 2023

Retrieved on: 
Monday, March 13, 2023
Swelling, Academy of Managed Care Pharmacy, Lymphedema, Dayspring, Edema, NILE, Gold, Poster, AMCP, Medical device

OAKLAND, Calif., March 13, 2023 /PRNewswire/ -- Koya Medical, a healthcare company on a mission to transform venous and lymphatic care through innovative, people-centric solutions, today announced their selection for a poster presentation of the NILE Trial at the upcoming Academy of Managed Care Pharmacy (AMCP) conference being held March 21-24, 2023, in San Antonio, Texas.

Key Points: 
  • OAKLAND, Calif., March 13, 2023 /PRNewswire/ -- Koya Medical, a healthcare company on a mission to transform venous and lymphatic care through innovative, people-centric solutions, today announced their selection for a poster presentation of the NILE Trial at the upcoming Academy of Managed Care Pharmacy (AMCP) conference being held March 21-24, 2023, in San Antonio, Texas.
  • The Dayspring device was found to be more effective than an APCD.
  • Participants experienced significantly greater mean reduction in edema (swelling caused by excess fluid trapped in the body's tissues) volume (64.6% vs. 27.7%; p
  • Significantly greater adherence (95.6% vs. 49.8%), and greater satisfaction (90% vs. 14%) with the Dayspring device versus an APCD.

uniQure to Participate in Multiple Upcoming Industry Conferences in March

Retrieved on: 
Thursday, March 2, 2023
Episcopal conference, AAV, MSHS, International Conference on Availability, Reliability and Security, Employment, CGC, Academy of Managed Care Pharmacy, Conference, Patient, Neurology, ALS, Doctor of Philosophy, Mutation, APOE, Muscular Dystrophy Association, USP, MDA, AMCP, SOD1, Pharmaceutical industry, Vaccine

Mr. Kapusta also will participate in a panel discussion, “Genetic Medicines Corporate Panel,” on March 6 from 10:30 – 11:30 a.m.

Key Points: 
  • Mr. Kapusta also will participate in a panel discussion, “Genetic Medicines Corporate Panel,” on March 6 from 10:30 – 11:30 a.m.
  • The live webcast of this event can be accessed through the link displayed in the Investors & Media section of the uniQure website.
  • Members of uniQure’s management team will participate in virtual investor meetings on Tuesday, March 28.
  • The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Media section of the uniQure website.

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Retrieved on: 
Wednesday, January 18, 2023
Associate, Gastroparesis, Dehydration, Malnutrition, DGP, Absorption, AMCP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ER, FDA, Academy of Managed Care Pharmacy, Metoclopramide, Patient, Food, UC San Diego Health, CST, Pharmaceutical industry, Medicine

Prior to GIMOTI’s approval by the U.S. Food and Drug Administration (FDA), oral metoclopramide was the only FDA-approved outpatient treatment for patients suffering from DGP.

Key Points: 
  • Prior to GIMOTI’s approval by the U.S. Food and Drug Administration (FDA), oral metoclopramide was the only FDA-approved outpatient treatment for patients suffering from DGP.
  • The poster presentation at the AMCP annual meeting will cover the data from a retrospective cohort analysis of 294 patients receiving nasal metoclopramide (GIMOTI).
  • The presentation at the AMCP meeting will show how GIMOTI utilization is supporting the continuum of care for patients,” commented Chris Quesenberry, Chief Commercial Officer for GIMOTI.
  • Details of the poster presentation are as follows:
    Presentation Date/Time: Thursday, March 23 from 11:30 a.m. – 2:30 p.m. CST

Mednow Achieves Record Q1 2023 Financial Results with Quarterly Revenue of $9.7 Million; 35% Q/Q Revenue Growth and 1,300% Y/Y Revenue Growth; Costs Down 30% and Cash Flow from Operations Improved by 38% Q/Q

Retrieved on: 
Wednesday, January 18, 2023
Other Health, Health, Pharmaceutical, Telemedicine, Virtual Medicine, Managed Care, Consensus, Cloud, Pharmacist, Inc., Conversation, Academy of Managed Care Pharmacy, Practitioner, EBITDA, TC, Communication, PPN, City centre, Arista Networks, Pharmacy, TSX, NYSE, SG, Adjustment, Marketing, Growth, GTA, Patient, Pension, Software, Physician, Prescription, Longest increasing subsequence, CAPEX, MFB, Traction, Disclosure, Business, Pharmaceutical industry, Risk management, Health insurance, Maple syrup, Distribution (marketing), Healthcare, Hospital, Fine chemical, Video game, Bookkeeping, Tucows

The resulting merged entities produce more revenue from cross-selling and have less overall costs for the Company.

Key Points: 
  • The resulting merged entities produce more revenue from cross-selling and have less overall costs for the Company.
  • Mednow continues to own and operate pharmacies in Ontario and British Columbia along with a franchise in the province of Quebec.
  • Refer to the disclosure under the heading “Definitions of Certain Non-IFRS Financial Measures” for more information on this non-IFRS financial measure.
  • Refer to the disclosure under the heading “Definitions of Certain Non-IFRS Financial Measures” for more information on this non-IFRS financial measure.

Mednow Enters Into National Distribution and Preferred Pharmacy Network (PPN) Agreement With Care Pharmacies; Announces Grant of Management Cease Trade Order

Retrieved on: 
Wednesday, January 4, 2023
General Health, Health, Pharmaceutical, Health Technology, Telemedicine, Virtual Medicine, Work, British Columbia Securities Commission, TSX Venture Exchange, Pharmacy, CFO, National Policy, Interim, Inc., News, Person, Patient, SEDAR, Attention, Collection, PPN, Indian stock exchange, Academy of Managed Care Pharmacy, Documentation, SAAS, Audit

Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF) Canada’s on-demand pharmacy, enhances its national virtual pharmacy offering by partnering with Care Pharmacies.

Key Points: 
  • Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF) Canada’s on-demand pharmacy, enhances its national virtual pharmacy offering by partnering with Care Pharmacies.
  • In addition to owned Mednow central-fill pharmacies, any pharmacies that are part of the Mednow PPN will enable Mednow to service more Canadians with localized pharmacy fulfillment.
  • Mednow will collect fees for membership in the PPN, technology fees and other SAAS fees related to the virtual services provided by Mednow.
  • Mednow announces today that further to its news release dated December 15, 2022, the Company has been granted a Management Cease Trade Order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") by the British Columbia Securities Commission.

Priority Health executive to serve as president of national pharmacy board

Retrieved on: 
Monday, December 19, 2022
Professional Services, Health, Insurance, Health Insurance, Managed Care, General Health, Pharmaceutical, Pharmacist, Patient, Population Health Management, Newsroom, Health, Nursing, Barrington, AMCP, Medicare, News, Spectrum Health, Economics, University of Health Sciences and Pharmacy in St. Louis, Medicaid, Physician, University Medical Center, Research group, Forecasting, Academy of Managed Care Pharmacy, Hospital, Healthcare, Pharmacy

Christina Barrington, vice president of pharmacy programs at Priority Health, will serve as president-elect of the 2023-2024 Board of Directors for the Academy of Managed Care Pharmacy (AMCP).

Key Points: 
  • Christina Barrington, vice president of pharmacy programs at Priority Health, will serve as president-elect of the 2023-2024 Board of Directors for the Academy of Managed Care Pharmacy (AMCP).
  • She will then serve as president of the Board of Directors in 2024-2025.
  • AMCP is a professional organization dedicated to improving patient health by ensuring access to high-quality, cost-effective medications and other therapies.
  • “As a longtime member of the AMCP board, I am honored to be elected to serve as president-elect and president to help advance the academy’s strategic direction,” said Barrington.

MESMERIZE EXPANDS ITS PHARMACY NETWORK TO INCLUDE CARE PHARMACIES COOPERATIVE

Retrieved on: 
Thursday, December 15, 2022
Pharmacy, Patient satisfaction, Literature, Academy of Managed Care Pharmacy, Partnership, Patient, Privacy, Individual, CARE, Prescription, Caregiver, Senior, Growth, Education, Hospital, Mesmerize

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Mesmerize ( www.mesmerize.com ), a prominent out-of-home media company specializing in patient education at the point of care, announced the expansion of its pharmacy network to include a preferred partner agreement with CARE Pharmacies Cooperative .

Key Points: 
  • NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Mesmerize ( www.mesmerize.com ), a prominent out-of-home media company specializing in patient education at the point of care, announced the expansion of its pharmacy network to include a preferred partner agreement with CARE Pharmacies Cooperative .
  • CARE Pharmacies Cooperative, the 2021 Regional Drug Chain of the Year, comprises over 130 locations nationwide and is expanding.
  • Mesmerize is also working with individual CARE Pharmacies to create custom messaging educating consumers on pharmacy products and specialty services.
  • CARE Pharmacies Cooperative combines the quality of an independent pharmacy with the infrastructure and continuity of a regional drug chain.